Celgene Corp. PT Raised to $197.00 at Leerink Swann (CELG)
Investment analysts at Leerink Swann lifted their target price on shares of Celgene Corp. (NASDAQ:CELG) from $177.00 to $197.00 in a note issued to investors on Tuesday, StockRatingsNetwork.com reports. Leerink Swann’s price objective would indicate a potential upside of 17.94% from the company’s current price.
CELG has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Celgene Corp. from $185.00 to $197.00 in a research note to investors on Tuesday. Separately, analysts at Brean Capital raised their price target on shares of Celgene Corp. from $191.00 to $233.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Celgene Corp. from $173.00 to $182.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. Celgene Corp. currently has an average rating of “Buy” and an average price target of $166.40.
Shares of Celgene Corp. (NASDAQ:CELG) traded up 1.30% on Tuesday, hitting $167.04. 3,895,530 shares of the company’s stock traded hands. Celgene Corp. has a 1-year low of $96.30 and a 1-year high of $174.66. The stock has a 50-day moving average of $165.9 and a 200-day moving average of $150.. The company has a market cap of $68.832 billion and a price-to-earnings ratio of 47.48. Celgene Corp. also saw unusually large options trading activity on Monday. Stock investors purchased 26,795 call options on the stock. This is an increase of 291% compared to the average volume of 6,854 call options.
Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, October 24th. The company reported $1.56 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the company posted $1.29 earnings per share. Celgene Corp.’s revenue was up 18.0% compared to the same quarter last year. On average, analysts predict that Celgene Corp. will post $6.00 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.